AGIO Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc (AGIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $914.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 30,000 | $30.48 | $914.4K | 54,645 −35.4% of holding | |
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 4,007 | $37.56 | $150.5K | 84,645 −4.5% of holding | |
| Goff Brian 2 fills | Chief Executive Officer | Sell 10b5-1 | 19,068 | $34.71 | $661.9K | 184,508 −9.4% of holding | |
| Burns James William | Chief Legal Officer | Sell 10b5-1 | 3,280 | $34.71 | $113.8K | 49,306 −6.2% of holding | |
| Milanova Tsveta | Chief Commercial Officer | Sell 10b5-1 | 3,262 | $34.71 | $113.2K | 46,829 −6.5% of holding | |
| Jones Cecilia | Chief Financial Officer | Sell 10b5-1 | 3,141 | $34.71 | $109.0K | 54,998 −5.4% of holding | |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy | Sell 10b5-1 | 2,959 | $34.71 | $102.7K | 10,282 −22.3% of holding | |
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 2,940 | $34.71 | $102.0K | 80,277 −3.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.